Braxia Scientific Corp, a Canadian medical research company founded in 2019, is leading the way in the mental health science industry with its innovative approach. The company's focus on providing ketamine treatments for individuals suffering from depression and related disorders sets it apart in the field of manufacturing medical solutions.
Braxia's recent $3.00M Post-IPO Equity investment on 06 January 2022 highlights its strong growth trajectory and potential for further expansion. The successful investment underscores the confidence that investors have in the company's vision and the value it brings to the mental health space.
With its dedication to pioneering mental health treatments, Braxia Scientific Corp is positioned as a key player in shaping the future of mental health science, offering promising potential for both impact and returns for prospective venture capitalists.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Post-IPO Equity | $3.00M | - | 06 Jan 2022 | |
Post-IPO Equity | $15.00M | 1 | Gravitas Securities | 11 Jun 2020 |
No recent news or press coverage available for Braxia Scientific Corp.